Plutux
$0.70
-9.71%
2026-09-03 16:00:01 EDT-$0.07
Technology
Software - Infrastructure
NASDAQ
Active Trading

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its ...

Price Action

$0.70
-9.71%-$0.07
High
Low
52W High-89.3%
Rel. vol
Interval
Range4.6h
VolumeSMA5SMA10
AIxCrypto Holdings, Inc. (NASDAQ: AIXC) is headquartered in Carlsbad, California, and was founded in 1996. The company’s public description indicates a dual narrative: (1) a clinical-stage biopharmaceutical focus on discovering and developing treatments for adult and pediatric oncology, and (2) a technology ecosystem direction that integrates artificial intelligence with blockchain ...AIxCrypto Holdings, Inc. (NASDAQ: AIXC) is headquartered in Carlsbad, California, and was founded in 1996. The company’s public description indicates a dual narrative: (1) a clinical-stage biopharmaceutical focus on discovering and developing treatments for adult and pediatric oncology, and (2) a technology ecosystem direction that integrates artificial intelligence with blockchain while aiming to bridge Web2 and Web3. From the biopharmaceutical perspective, the company highlights QN-302, a small molecule described as a G-quadruplex (G4)-selective transcription inhibitor. QN-302 is characterized as progressing through Phase I clinical trials for pancreatic cancer and other solid tumors. In addition, the company references Pan-RAS as a preclinical-stage program targeting advanced solid tumors. These program stages suggest an R&D-heavy operating model typical of early-stage oncology development companies, where external financing, clinical milestones, and continued investment in drug discovery are key to progress. From the technology and ecosystem perspective, supplied notes describe AIxCrypto as building an AI + blockchain ecosystem and developing initiatives intended to connect traditional internet (Web2) users with decentralized systems (Web3). While specific technical product details are not provided in the excerpt, the company’s positioning implies an emphasis on platform strategy, community/participant tooling, and AI-enabled experiences or infrastructure layered with blockchain components. In terms of scale, the provided data lists approximately 10 full-time employees (and also references a “51–200 employees” range in other summaries). Given the direct “Full Time Employees: 10” field in the provided dataset, the employee size bucket is treated as the closest match: 0–100 employees. The combination of a small team and multiple development tracks (clinical/preclinical drug programs plus technology ecosystem initiatives) typically indicates a lean corporate structure with reliance on scientific collaborators, contract research organizations, and partners for execution. Cost and financial profile information in the dataset (e.g., operating/return metrics and negative cash-flow indicators in a TTM snapshot) is consistent with early-stage investment cycles where revenue may be limited and cash burn can occur as clinical and platform efforts proceed. Key leadership is identified as Jiawei Wang (CEO) in the provided data; additional leadership references exist but vary across sources, so Jiawei Wang is used as the CEO name where explicitly stated. Overall, AIxCrypto presents itself as a repositioned public company (rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025 per the description) aiming to pursue oncology therapeutics alongside an AI+blockchain ecosystem strategy. Investors and stakeholders would typically look for updates on clinical progress for QN-302, advancement of preclinical Pan-RAS, and tangible milestones demonstrating the commercial traction of its AI/Web3 ecosystem initiatives.
Founded
1996
Employees
10
CEO
Jiawei Wang
Full Name
AIxCrypto Holdings, Inc.
Sector
Technology
Industry
Software - Infrastructure
ROE
-97.40%
Market Cap
$0.01B
Current Ratio
3.68
WACC
56.01%
ROIC
-393.55%

Contact Information

760 452 8111
1990 E Grand Ave, El Segundo, CA 90245

Related stocksMedical - Pharmaceuticals

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026